Genetic drugs based on nucleic acid biomolecules are a rapidly emerging class of
medicines that directly reprogramme the central dogma of biology to prevent and treat …

The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …

RNA-based therapeutics have shown tremendous promise in disease intervention at the
genetic level, and some have been approved for clinical use, including the recent COVID-19 …

To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …

RNA-based gene therapy requires therapeutic RNA to function inside target cells without
eliciting unwanted immune responses. RNA can be ferried into cells using non-viral drug …

Safe and efficacious systemic delivery of messenger RNA (mRNA) to specific organs and
cells in vivo remains the major challenge in the development of mRNA-based therapeutics …

Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …

mRNA vaccines have been demonstrated as a powerful alternative to traditional
conventional vaccines because of their high potency, safety and efficacy, capacity for rapid …

RNA-based therapeutics have shown great promise in treating a broad spectrum of
diseases through various mechanisms including knockdown of pathological genes …

Lipid nanoparticles (LNPs) for the efficient delivery of drugs need to be designed for the
particular administration route and type of drug. Here we report the design of LNPs for the …